Can I delay knee replacement with cartilage repair

Between painkillers and a full knee replacement, there is often a “middle ground” for certain knees — especially when the problem is localised cartilage damage or wear concentrated in one compartment rather than the whole joint being worn out.

A practical way to think about knee care is a four-step pathway:

• Symptom management (physiotherapy, activity adjustment, weight optimisation, bracing and pain-relief medicines)
• Biologic / injection support (for example, injections aimed at calming pain and swelling rather than rebuilding joint surfaces)
• Cartilage restoration or scaffold repair (procedures designed to repair a defined defect)
• Joint replacement (unicompartmental or total knee arthroplasty) when the surfaces are globally worn and symptoms remain limiting

The “cartilage repair” conversation usually applies when imaging shows a contained defect (sometimes described on reports as Outerbridge or ICRS “grade 3–4”) with enough healthier cartilage around it to build on. That is different from diffuse, end-stage osteoarthritis, where most of the joint surfaces are affected and replacement is more often the definitive option.

When joint preservation is appropriate, the mechanisms differ — and that is why the evidence is discussed in separate blocks. Realignment osteotomy aims to buy time by shifting load away from the worn side: a 20-year prospective HTO series reported 44% survivorship at 20 years, rising to 62% in a favourable subgroup (for example <55 years and BMI <30) with 97% satisfaction among surviving knees; a 2024 systematic review in radiographically advanced medial OA reported average 10-year survivorship ~74.6%. Cartilage repair surgery targets the defect itself: a minimum 10-year MACI review (10–17 years) reported durable symptom improvement, 9% reoperation, and 7.4% progression to TKA. Across techniques, a 2024 meta-analysis of 47 studies (1,993 patients) found ACI, MACI, OAT and OCA each produced clinically meaningful score improvements, suggesting several routes can delay the need for replacement when matched to the knee’s pattern of damage.

To avoid a “drumbeat” of product placement, specific brands and clinics are not repeated here; later sections cover newer injectable scaffold approaches (including Liquid Cartilage™) in a more focused, evidence-led way.

When osteotomy is used instead of knee replacement

Osteotomy is joint-preserving realignment surgery: a planned cut in the shin bone (high tibial osteotomy, HTO) or thigh bone (distal femoral osteotomy, DFO) changes the leg’s alignment so body weight is shifted away from the worn compartment. In a bow‑legged (varus) knee with mainly medial wear, HTO aims to move load laterally; in a knock‑kneed (valgus) knee with mainly lateral wear, DFO aims to move load medially.

Candidate selection is where osteotomy tends to differ most from replacement. State-of-the-art reviews describe medial opening-wedge HTO as best suited to younger, active patients with symptomatic medial unicompartmental osteoarthritis and varus malalignment, emphasising careful patient selection and individualised planning.

Durability can be meaningful, but it is not uniform. A 20‑year prospective series (100 knees) reported overall HTO survivorship of 44% at 20 years, improving to 62% in a “favourable” subgroup (including age <55 and BMI <30), with 97% satisfaction among knees that had not converted. In radiographically advanced medial osteoarthritis, a 2024 systematic review (18 studies, 1,296 knees) still reported average 10‑year survivorship of about 74.6% and patient‑reported outcomes generally meeting accepted thresholds for “feeling better”.

The trade‑off is that osteotomy is a bone‑healing procedure with real complication and re‑operation risk. A large systematic review (7,836 patients) reported intraoperative complications in 5.5% and postoperative complications in 6.9%, including lateral hinge fracture around 9.1% in medially based HTOs and superficial infection around 2.2%.

Biomechanical testing also suggests that procedure choice can change unloading through the range of motion. In a model using an 8° varus correction for valgus knees, medial closing-wedge HTO reduced lateral compartment pressures more than lateral opening-wedge DFO at higher flexion angles (60°–90°).

• Bottom line from the published data: osteotomy most reliably “buys time” by changing load in a single-compartment, malaligned knee, but the “price” is a longer bone-healing phase and a meaningful chance of complications and later procedures; knee replacement tends to be more predictable for pain relief in older, more globally arthritic knees.

Choosing between ACI MACI and other surgical repairs

For many people weighing up ACI, MACI and graft-based repairs, the deciding issue is not the acronym but the treatment journey: whether the knee problem is best served by a planned two-stage cell procedure (more operations, more logistics) or a single-operation graft (more immediate structural “fill”, but limited by graft size and donor/availability constraints).

When a two-stage cell procedure may be worth it (ACI → MACI)

In many clinical pathways, autologous chondrocyte implantation (ACI) is approached as a staged process: a first procedure collects a small cartilage sample, cells are expanded in a laboratory over subsequent weeks, and a second procedure implants cultured cells into the defect. The upside is a biologically targeted attempt to rebuild cartilage-like tissue in a defined defect; the trade-off is the deliberate requirement for two separate procedures and two recovery episodes.

MACI (matrix-induced ACI) follows the same “biopsy → culture → implant” logic but uses a scaffold/membrane-based delivery of the cultured cells.

Who these operations are usually aimed at (and why mechanics still matter)

In specialist practice, ACI/MACI are generally discussed for contained, full‑thickness chondral defects (often described as ICRS grade 3–4) where the knee’s alignment and stability are acceptable (or addressed as part of the plan).

How this compares with grafting options (OATS/OCA) and what the evidence says overall

Graft-based procedures (often grouped as OATS/OAT for autograft and OCA for allograft) aim to restore a defect by transplanting cartilage with underlying bone; in day-to-day decision-making, they are often considered when a lesion’s location and bone involvement makes a structural graft attractive, balanced against donor-site limits (autograft) or graft access (allograft). At a big-picture level, a 2024 meta-analysis found that ACI, MACI, OATS and OCA were each associated with clinically meaningful improvements in pain and function scores, without establishing one technique as clearly “best” for every scenario—so lesion characteristics, prior surgery, and the operating team’s experience tend to drive real-world choices.

Longer follow-up is often where patients most want reassurance. In a minimum 10‑year MACI report (168 patients; 188 defects, with follow-up extending to 17 years), published outcomes suggested improvements were generally maintained, MRI commonly showed satisfactory graft fill, and only a minority of cases moved on to further surgery or eventual knee replacement.

These strengths—especially the track record of cell-based repairs—also explain why newer single-stage scaffold approaches, including injectable collagen scaffolds, have attracted interest: the aim is to capture some of the biological upside while reducing the burden of multiple operations.

How injectable scaffolds compare with cell based surgery

Scaffold-guided cartilage repair shifts the emphasis from implanting cultured cells to creating the right structure inside the defect. Instead of a laboratory expanding millions of chondrocytes for a second operation (as in ACI/MACI), the core idea is to place an acellular (or low‑cell) matrix into a contained, prepared lesion, so that the body’s own repair cells can populate it and form cartilage‑like tissue.

Some single-stage approaches combine a scaffold with marrow-derived biologic augmentation (for example, bone-marrow-derived concentrates), aiming to improve defect fill and avoid a planned second operation. However, compared with established cell-based programmes, the evidence base for many injectable scaffold systems is still earlier-stage, and long-term durability (for example 10+ years) is less consistently reported.

Takeaway: scaffold approaches most clearly change the setting and number of procedures (often one stage), they do not remove the need for the right underlying mechanics and a focal target lesion, and the main “unknown” remains how reliably different scaffold systems match the 10+ year durability reported in longer-running cell-based series.

Where STACI sits in modern cartilage repair

STACI (often written as “single‑treatment ACI”) is commonly used to describe a family of one‑stage, theatre‑based cartilage procedures designed to address a practical limitation in classic ACI/MACI: the need for two separate operations (biopsy first, then implantation weeks later).

On the day of surgery, single-stage autologous cartilage workflows are often described as: harvesting a small amount of healthier cartilage from a low‑load area, processing it so that cartilage-forming cells can be used immediately, then combining these with a carrier/scaffold and placing the construct back into the defect in the same sitting. The detail varies by centre and technique, which is part of why “STACI” is best thought of as a category rather than a single standardised operation.

Evidence for many single-stage cell-handling approaches remains earlier-stage than established MACI programmes, with less long follow-up available.

Conceptually, this places single-stage autologous cell-handling approaches between MACI and fully acellular injectable scaffolds:

• MACI/ACI: cultured cells and a planned second operation.
• Single-stage autologous cartilage repair (STACI-style): intra‑operative cell handling and scaffold/carrier placement in one theatre sitting.
• Acellular injectable scaffolds: no cartilage harvest and no cell processing; instead an acellular scaffold is placed into a focal defect, relying on host cell recruitment rather than implanting chondrocytes on the day.

Planning your pathway at the London Cartilage Clinic

Planning usually starts with clarifying what problem the knee is actually presenting: a single, contained cartilage defect (often described on MRI as ICRS/Outerbridge grade 3–4) versus a more global osteoarthritic pattern (for example, Kellgren–Lawrence grade 3–4 across compartments). The pathway below keeps the emphasis on decision points used in specialist cartilage consultations, rather than on any one provider.

In a typical specialist assessment, the work-up combines a detailed history (injury date, swelling episodes, giving-way), an examination of stability and patellar tracking, and a structured review of imaging. It is common to refresh imaging with an up-to-date MRI (to define defect size, “containment”, and subchondral bone status) plus weight‑bearing alignment X‑rays (to quantify varus/valgus mechanics that can drive compartment overload).

Once the problem is defined, options are usually weighed using a small set of practical filters: limb alignment, defect size and grade, age and activity goals, and any previous surgery that may have altered the subchondral plate. This is where decision-making tends to separate into:

• Image-guided injectable scaffold pathways when the target is a focal, mechanically suitable lesion.
• Theatre-based cartilage restoration (for example, MACI/ACI or graft procedures) when defect characteristics and goals justify a more invasive programme.
• Realignment osteotomy when mechanics are the limiting issue, sometimes as an adjunct to restoration.
• Arthroplasty planning when wear is diffuse and joint preservation is unlikely to be durable.

1. [1] Autologous chondrocyte implantation, matrix-induced autologous chondrocyte implantation, osteochondral autograft transplantation and osteochondral allograft improve knee function and pain with considerations for patient and cartilage defects characteristics: A systematic review and meta-analysis. (2024). https://doi.org/10.1002/ksa.12525 https://doi.org/10.1002/ksa.12525